The investigation revealed that Aveo Pharmaceuticals, based in Mumbai, has been illegally exporting a combination of these highly addictive drugs, which together pose serious health risks including respiratory failure, seizures, and even death upon overdose. The Indian Food and Drug Administration conducted a raid on Aveo’s facilities, seizing its entire stock and halting future production. Notably, Aveo's director acknowledged the danger of the cocktail drug but presented it as a lucrative business opportunity. The government has committed to further inspections and legal actions against entities involved in this illicit trade, signaling a strong stance on pharmaceutical accountability and public health safety.

The escalating opioid crisis in West Africa has drawn international attention, with Nigeria emerging as a significant market where an estimated four million individuals are caught in the cycle of opioid abuse. The ban from India comes as a necessary intervention to curb the flow of these dangerous drugs, reinforcing the need for global cooperation in tackling the opioid epidemic.

As global scrutiny intensifies on the pharmaceutical industry's involvement in health crises, India's prompt action highlights the intersections between public health, regulation, and international trade.

This decisive action signals a pivotal moment in the fight against the opioid crisis that has gripped many vulnerable populations worldwide.